科研之友
微信
新浪微博
Facebook
分享链接
摘要
A new class of non-agonist ligands target the transcription factor PPAR gamma and promote expression of insulin-sensitizing adipokines. They have potent antidiabetic actions, yet they lack several of the adverse effects commonly associated with thiazolidinediones. The ligands may represent a new class of anti-diabetes medications that preserve the most beneficial effects of PPAR gamma activation without imparting major side effects, which have limited the clinical usefulness of thiazolidinediones.
- 出版日期2012-1-6
